Latest Funding News

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Cobre Limited has had its trading suspension lifted immediately following the announcement of a significant acquisition and capital placement, signalling a pivotal moment for the base metals miner.

Cobre Limited has secured A$60 million to acquire a majority stake in the Sierra Atacama Copper Project in Chile, positioning itself as a significant copper producer with strong expansion potential.

US1 Critical Minerals has provided clarity on the issuance of 50 million fee options to consultants related to its December 2025 placement, reaffirming shareholder approval is pending and no funds will be raised from this issuance.

Enova Mining has successfully raised $2 million through a heavily oversubscribed share placement, enabling accelerated drilling and test work at its East Salinas and Charley Creek projects. This capital injection positions the company to advance its critical minerals exploration amid growing demand for rare earth elements.

Paladin Energy reported a 16% increase in uranium production and a significant rise in sales volumes for the December 2025 quarter, alongside a successful equity raise and debt restructuring that enhance its financial flexibility.

European Resources Limited has reported promising drill results with strong neodymium-praseodymium enrichment at its Korsnäs rare earth project in Finland, alongside advancing metallurgical test work aimed at optimising extraction processes.

Paladin Energy reported a stronger half-year performance with US$138.3 million revenue from uranium sales, a narrowed net loss, and a successful A$400 million equity raise to fund growth projects.

Dundas Minerals has raised $2.5 million through a strongly supported share placement to fund gold exploration drilling at its Kalgoorlie and expanded Romano projects in Western Australia.

ASX Limited reported robust half-year results with an 11.2% rise in operating revenue and a steady net profit, while advancing its technology upgrade and responding to regulatory scrutiny.

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.

OncoSil Medical’s CEO Nigel Lange has agreed to a 10% salary reduction, opting instead to receive shares at a significant premium, reinforcing executive commitment to shareholder value and cost discipline.